Lipid-Modifying Agents, From Statins to PCSK9 Inhibitors
نویسندگان
چکیده
منابع مشابه
PCSK9 Inhibitors
Alirocumab and evolocumab are monoclonal antibodies that block proprotein convertase subtilisin/kexin type 9 (PCSK9), a circulating protein that degrades low-density lipoprotein (LDL) receptors. These therapies increase LDL receptors on the cell surface and reduce plasma LDL cholesterol. Both therapies are approved to lower LDL cholesterol, a causative agent for atherosclerotic cardiovascular d...
متن کاملPCSK9 inhibitors: A new era of lipid lowering therapy
Hyperlipidemia is a well-established risk factor for developing cardiovascular disease (CVD). The recent American College of Cardiology and American Heart Association guidelines on lipid management emphasize treatment of individuals at increased risk for developing CVD events with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) at doses proven to reduce CVD events. However,...
متن کاملStatins: Newer Roles Including Lipid Lowering Therapy
Statins are most effective pharmacologically agents to decrease total plasma cholesterol level by competitive inhibition of HMG-Co A reductase. Apart from the well-known LDL and cholesterol lowering effect, statins have been postulated to exert other beneficial effects also called pleotropic or non-lipid effects. Better understanding of various pleotropic effects of statins has prompted a new s...
متن کاملPCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
Current guidelines for hypercholesterolemia treatment emphasize lifestyle modification and lipid-modifying therapy to reduce the risk for cardiovascular disease. Statins are the primary class of agents used for the treatment of hypercholesterolemia. Although statins are effective for many patients, they fail to achieve optimal reduction in lipids for some patients, including those who have or a...
متن کاملUse of lipid-lowering agents (statins) during pregnancy.
QUESTION A 34-year-old patient of mine is taking a 'statin' for hyperlipidemia. She is planning pregnancy and is worried about the safety of the drug. How should I advise her? ANSWER Limited evidence from animal and human studies indicates that statins should not be taken during pregnancy. If a patient is inadvertently exposed during pregnancy, however, termination does not appear to be medic...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of the American College of Cardiology
سال: 2020
ISSN: 0735-1097
DOI: 10.1016/j.jacc.2019.11.072